Business
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Company executes on corporate communication strategy and advances drug branding initiatives Lead drug candidate for NSCLC now referred to as quaratusugene
About this update from Genprex, Inc.
[{"type":"text","content":"\nCompany executes on corporate communication strategy and advances drug branding initiatives\n\n\nLead drug candidate for NSCLC now referred to as quaratusugene ozeplasmid or GPX-001\n\n\nCompany rebrands use of Oncoprex™ name for Nanoparticle Delivery Platform \n\n AUSTIN, Texas--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex™ immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (NSCLC).\n\n\nThe USAN Council is responsible for selecting simple, informative, and unique non-proprietary (generic) drug names. As a part of Genprex’s corporate communication strategy and drug nomenclature branding, the Company is also pursuing formal proprietary brand name approval for its lead drug candidate, GPX-001 (quaratusugene ozeplasmid). Obtaining regulatory approval of these adopted drug names is a necessary step in securing marketing approval.\n\n\nIn conjunction with the adoption of quaratusugene ozeplasmid as the Company’s non-proprietary name for GPX-001, Genprex has rebranded the naming of its unique, proprietary, non-viral nanoparticle delivery system, now referred to as its Oncoprex™ Nanoparticle Delivery Platform, which is the vehicle used to deliver its oncology platform technologies.\n\n\n“The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway. In the meantime, we’ve focused our branding efforts on our proprietary, non-viral nanoparticle delivery system with our recognized Oncoprex™ name. We believe this delivery system is a significant differentiator for GPX-001, as well as an important platform delivery system that could be used for additional drug candidates.”\n\n\nAs a part of the rollout of its newly adopted nomenclature and to also include its gene therapy drug ca...